middle.news
Patrys Advances PAT-DX3 Amid Cash Pressures and Strategic Licensing Moves
5:00am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Patrys Advances PAT-DX3 Amid Cash Pressures and Strategic Licensing Moves
5:00am on Monday 2nd of June, 2025 AEST
Key Points
PAT-DX3 development focus shifts to inflammatory diseases
Cash balance at $854,000 with $790,000 R&D tax refund expected
Net cash outflow of $1.345 million in Q1 2025, driven by R&D costs
Cost reduction initiatives and workforce downsizing underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE